| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 2.785 | 2.917 | - | 3.169 | 2.868 | 3.288 | 2.113 | 1.110 | 2.204 | 1.878 |
| Total Income - EUR | 2.785 | 2.917 | - | 3.169 | 2.868 | 3.288 | 2.113 | 1.110 | 2.204 | 1.878 |
| Total Expenses - EUR | 1.921 | 2.363 | - | 2.439 | 2.712 | 3.881 | 1.966 | 900 | 1.855 | 1.500 |
| Gross Profit/Loss - EUR | 864 | 554 | - | 730 | 156 | -593 | 146 | 210 | 348 | 379 |
| Net Profit/Loss - EUR | 781 | 467 | - | 635 | 70 | -683 | 84 | 179 | 279 | 255 |
| Employees | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Daralex-Radmed S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 998 | 988 | - | 953 | 935 | 652 | 436 | 235 | 34 | 0 |
| Current Assets | 1.759 | 2.377 | - | 3.227 | 3.155 | 2.968 | 2.876 | 3.263 | 3.749 | 4.000 |
| Inventories | 1.188 | 1.176 | - | 1.468 | 1.440 | 999 | 674 | 676 | 0 | 0 |
| Receivables | 0 | 0 | - | 408 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash | 571 | 1.201 | - | 1.351 | 1.715 | 1.969 | 2.203 | 2.587 | 3.749 | 4.000 |
| Shareholders Funds | 893 | 1.351 | - | 4.053 | 4.045 | 3.285 | 3.296 | 3.486 | 3.754 | 3.988 |
| Social Capital | 45 | 45 | - | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 2.372 | 2.125 | - | 127 | 45 | 335 | 16 | 13 | 28 | 12 |
| Income in Advance | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Daralex-Radmed S.r.l.